SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'ZG2'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UHO_A_VDNA1000_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 10	TYR A 233 HIS A 234 PHE A 414 GLN A 443 GLY A 445 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.9A) ZG2 A 506 (-3.6A)	0.48A	1uhoA-3o57A: 36.2	1uhoA-3o57A: 28.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 274 MET A 347 THR A 407 GLN A 443 PHE A 446	ZN A 1 (-3.3A) ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	1.47A	1xlxA-3o57A: 53.5	1xlxA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_A_CIOA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 HIS A 278 MET A 347 LEU A 393 ASN A 395 THR A 407 ILE A 410 MET A 411 SER A 442 GLN A 443 PHE A 446	None None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.55A	1xlxA-3o57A: 53.5	1xlxA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 274 MET A 347 THR A 407 GLN A 443 PHE A 446	ZN A 1 (-3.3A) ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	1.47A	1xlxB-3o57A: 53.5	1xlxB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 HIS A 278 MET A 347 THR A 407 ILE A 410 MET A 411 PHE A 414 MET A 431 GLN A 443 PHE A 446	None None None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.59A	1xlxB-3o57A: 53.5	1xlxB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XLX_B_CIOB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 HIS A 278 MET A 347 THR A 407 ILE A 410 MET A 411 PHE A 414 MET A 431 SER A 442 PHE A 446	None None None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.70A	1xlxB-3o57A: 53.5	1xlxB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 ASP A 392 LEU A 393 PRO A 396 TYR A 403 TRP A 406 ILE A 410 PHE A 414 MET A 431 SER A 442 PHE A 446	None None ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.55A	1xmuA-3o57A: 54.3	1xmuA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_A_ROFA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 5	MET A 347 ASN A 395 THR A 407 MET A 411 GLN A 443	ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.3A) None ZG2 A 506 (-3.3A)	0.23A	1xmuA-3o57A: 54.3	1xmuA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TYR A 403 TRP A 406 ILE A 410 PHE A 414 MET A 431 SER A 442	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None	0.39A	1xmuB-3o57A: 53.6	1xmuB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XMU_B_ROFB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 5	ASN A 395 THR A 407 MET A 411 GLN A 443 PHE A 446	ZG2 A 506 (-4.3A) ZG2 A 506 (-4.3A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.56A	1xmuB-3o57A: 53.6	1xmuB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_A_CIOA603_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 ILE A 410 MET A 411 PHE A 414 MET A 431 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.66A	1xomA-3o57A: 52.3	1xomA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 THR A 407 ILE A 410 MET A 411 MET A 431 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.64A	1xomB-3o57A: 51.9	1xomB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOM_B_CIOB601_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 THR A 407 ILE A 410 MET A 411 PHE A 414 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.59A	1xomB-3o57A: 51.9	1xomB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TYR A 403 THR A 407 ILE A 410 MET A 431 SER A 442 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.59A	1xoqA-3o57A: 52.2	1xoqA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_A_ROFA502_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ASN A 395 TRP A 406 GLN A 443	ZG2 A 506 (-4.3A) None ZG2 A 506 (-3.3A)	0.11A	1xoqA-3o57A: 52.2	1xoqA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 ASP A 392 LEU A 393 PRO A 396 TYR A 403 TRP A 406 THR A 407 ILE A 410 MET A 431 SER A 442 PHE A 446	None None ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.58A	1xoqB-3o57A: 51.8	1xoqB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOQ_B_ROFB501_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	MET A 347 ASN A 395 GLN A 443	ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-3.3A)	0.29A	1xoqB-3o57A: 51.8	1xoqB-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 MET A 411 PHE A 414 GLN A 443 PHE A 446 ILE A 450	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.52A	1xosA-3o57A: 53.2	1xosA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 MET A 411 PHE A 414 MET A 431 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.57A	1xosA-3o57A: 53.2	1xosA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOS_A_VIAA1_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	9 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 MET A 411 PHE A 414 SER A 429 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 (-4.4A) ARS A 3 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.91A	1xosA-3o57A: 53.2	1xosA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_A_VDNA101_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 ILE A 410 MET A 411 SER A 429 MET A 431 SER A 442 GLN A 443 PHE A 446 ILE A 450	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.4A) None ARS A 3 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.66A	1xotA-3o57A: 53.5	1xotA-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	10 / 12	TYR A 233 HIS A 234 ASN A 395 ILE A 410 MET A 411 SER A 429 MET A 431 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ARS A 3 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.75A	1xotB-3o57A: 53.4	1xotB-3o57A: 93.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XOT_B_VDNB102_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	11 / 12	TYR A 233 HIS A 234 MET A 347 LEU A 393 ASN A 395 ILE A 410 MET A 411 SER A 429 SER A 442 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.9A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ARS A 3 (-4.4A) None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.56A	1xotB-3o57A: 53.4	1xotB-3o57A: 93.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_A_VIAA901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 PHE A 414 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.59A	2h42A-3o57A: 36.0	2h42A-3o57A: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2H42_C_VIAC903_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	TYR A 233 LEU A 393 PHE A 414 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.60A	2h42C-3o57A: 35.7	2h42C-3o57A: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_A_EV1A1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	8 / 12	TYR A 233 HIS A 234 LEU A 393 ILE A 410 GLU A 413 PHE A 414 GLN A 443 PHE A 446	None None None ZG2 A 506 (-4.4A) None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.87A	2weyA-3o57A: 38.0	2weyA-3o57A: 27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WEY_B_EV1B1771_1 (CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 8	ILE A 410 PHE A 414 GLN A 443 PHE A 446	ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.47A	2weyB-3o57A: 37.8	2weyB-3o57A: 27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_A_VDNA1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 12	TYR A 233 HIS A 234 LEU A 393 PHE A 414 GLN A 443 PHE A 446	None None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.62A	3b2rA-3o57A: 31.3	3b2rA-3o57A: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B2R_B_VDNB1_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 LEU A 393 GLN A 443 PHE A 446	None None None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.61A	3b2rB-3o57A: 31.3	3b2rB-3o57A: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CZV_A_AZMA263_1 (CARBONIC ANHYDRASE 13)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 12	HIS A 238 HIS A 274 PHE A 446 THR A 345 VAL A 451	ZN A 1 (-3.3A) ZN A 1 (-3.3A) ZG2 A 506 (-3.6A) MG A 504 ( 4.9A) None	1.21A	3czvA-3o57A: undetectable 3czvB-3o57A: undetectable	3czvA-3o57A: 21.27 3czvB-3o57A: 21.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASN A 395 PRO A 396 TYR A 403 TRP A 406 THR A 407 ILE A 410 MET A 431 SER A 442 PHE A 446	None None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) None ZG2 A 506 (-3.6A)	0.53A	3g4lA-3o57A: 51.6	3g4lA-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_A_ROFA901_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ASP A 392 LEU A 393 GLN A 443	ZN A 1 (-2.6A) None ZG2 A 506 (-3.3A)	0.27A	3g4lA-3o57A: 51.6	3g4lA-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_B_ROFB902_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TRP A 406 THR A 407 ILE A 410 MET A 411 MET A 431 PHE A 446	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None ZG2 A 506 (-3.4A) ZG2 A 506 (-3.6A)	0.50A	3g4lB-3o57A: 51.5	3g4lB-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 ASN A 395 PRO A 396 TYR A 403 TRP A 406 THR A 407 ILE A 410 MET A 431	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 (-4.3A) ZG2 A 506 ( 4.5A) None None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A)	0.33A	3g4lC-3o57A: 51.7	3g4lC-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_C_ROFC903_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	SER A 442 GLN A 443 PHE A 446	None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.43A	3g4lC-3o57A: 51.7	3g4lC-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_0 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	12 / 12	TYR A 233 HIS A 234 MET A 347 ASP A 392 LEU A 393 PRO A 396 TRP A 406 THR A 407 ILE A 410 MET A 411 SER A 442 GLN A 443	None None ZG2 A 506 (-3.9A) ZN A 1 (-2.6A) None ZG2 A 506 ( 4.5A) None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) None None ZG2 A 506 (-3.3A)	0.37A	3g4lD-3o57A: 52.2	3g4lD-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G4L_D_ROFD904_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	3 / 3	ASN A 395 MET A 431 PHE A 446	ZG2 A 506 (-4.3A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.6A)	0.68A	3g4lD-3o57A: 52.2	3g4lD-3o57A: 80.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 9	ILE A 410 MET A 431 GLN A 443 PHE A 446 ILE A 450	ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.81A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 9	MET A 347 ILE A 410 MET A 431 GLN A 443 PHE A 446	ZG2 A 506 (-3.9A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.95A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 9	TYR A 233 ASN A 395 ILE A 410 PHE A 414 GLN A 443 PHE A 446 ILE A 450	None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A) None	0.52A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IAK_A_EV1A415_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	7 / 9	TYR A 233 MET A 347 ASN A 395 ILE A 410 PHE A 414 GLN A 443 PHE A 446	None ZG2 A 506 (-3.9A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.77A	3iakA-3o57A: 51.2	3iakA-3o57A: 82.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_C_VIAC901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 7	TYR A 233 HIS A 234 GLN A 443 PHE A 446	None None ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.53A	3jwqC-3o57A: 39.1	3jwqC-3o57A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3JWQ_D_VIAD901_1 (CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 11	TYR A 233 HIS A 234 PHE A 414 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.58A	3jwqA-3o57A: 39.1 3jwqD-3o57A: 38.8	3jwqA-3o57A: 28.30 3jwqD-3o57A: 28.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 9	PRO A 396 THR A 407 ILE A 410 MET A 431 GLN A 443 PHE A 446	ZG2 A 506 ( 4.5A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.74A	3tvxA-3o57A: 52.8	3tvxA-3o57A: 86.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_A_PNXA902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	8 / 9	TYR A 233 LEU A 393 ASN A 395 PRO A 396 THR A 407 ILE A 410 GLN A 443 PHE A 446	None None ZG2 A 506 (-4.3A) ZG2 A 506 ( 4.5A) ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.40A	3tvxA-3o57A: 52.8	3tvxA-3o57A: 86.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	5 / 7	ASN A 395 ILE A 410 MET A 431 GLN A 443 PHE A 446	ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.88A	3tvxB-3o57A: 52.8	3tvxB-3o57A: 86.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TVX_B_PNXB902_1 (CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	6 / 7	TYR A 233 ASN A 395 ILE A 410 PHE A 414 GLN A 443 PHE A 446	None ZG2 A 506 (-4.3A) ZG2 A 506 (-4.4A) ZG2 A 506 (-4.4A) ZG2 A 506 (-3.3A) ZG2 A 506 (-3.6A)	0.51A	3tvxB-3o57A: 52.8	3tvxB-3o57A: 86.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562)	3o57	CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B (Homo sapiens)	4 / 6	ILE A 410 THR A 407 VAL A 281 ASP A 230	ZG2 A 506 (-4.4A) ZG2 A 506 (-4.3A) None None	1.09A	4iaqA-3o57A: undetectable	4iaqA-3o57A: 22.90

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1UHO_A_VDNA1000_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"TYR A 233;HIS A 234;PHE A 414;GLN A 443;GLY A 445;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.9A);ZG2 A 506 (-3.6A)","0.48A","1uhoA-3o57A:36.2",null],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 274;MET A 347;THR A 407;GLN A 443;PHE A 446"," ZN A   1 (-3.3A);ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","1.47A","1xlxA-3o57A:53.5","1uhoA-3o57A:28.03"],["1XLX_A_CIOA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;HIS A 278;MET A 347;LEU A 393;ASN A 395;THR A 407;ILE A 410;MET A 411;SER A 442;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.55A","1xlxA-3o57A:53.5","1xlxA-3o57A:93.83"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 274;MET A 347;THR A 407;GLN A 443;PHE A 446"," ZN A   1 (-3.3A);ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","1.47A","1xlxB-3o57A:53.5","1xlxA-3o57A:93.83"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;HIS A 278;MET A 347;THR A 407;ILE A 410;MET A 411;PHE A 414;MET A 431;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.59A","1xlxB-3o57A:53.5","1xlxB-3o57A:93.83"],["1XLX_B_CIOB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;HIS A 278;MET A 347;THR A 407;ILE A 410;MET A 411;PHE A 414;MET A 431;SER A 442;PHE A 446","None;None;None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.70A","1xlxB-3o57A:53.5","1xlxB-3o57A:93.83"],["1XMU_A_ROFA101_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;ASP A 392;LEU A 393;PRO A 396;TYR A 403;TRP A 406;ILE A 410;PHE A 414;MET A 431;SER A 442;PHE A 446","None;None; ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.55A","1xmuA-3o57A:54.3","1xlxB-3o57A:93.83"],["1XMU_A_ROFA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"MET A 347;ASN A 395;THR A 407;MET A 411;GLN A 443","ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.3A);None;ZG2 A 506 (-3.3A)","0.23A","1xmuA-3o57A:54.3","1xmuA-3o57A:93.83"],["1XMU_B_ROFB102_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TYR A 403;TRP A 406;ILE A 410;PHE A 414;MET A 431;SER A 442","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None","0.39A","1xmuB-3o57A:53.6","1xmuA-3o57A:93.83"],["1XMU_B_ROFB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ASN A 395;THR A 407;MET A 411;GLN A 443;PHE A 446","ZG2 A 506 (-4.3A);ZG2 A 506 (-4.3A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.56A","1xmuB-3o57A:53.6","1xmuB-3o57A:93.83"],["1XOM_A_CIOA603_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;ILE A 410;MET A 411;PHE A 414;MET A 431;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.66A","1xomA-3o57A:52.3","1xmuB-3o57A:93.83"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;MET A 347;LEU A 393;THR A 407;ILE A 410;MET A 411;MET A 431;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.64A","1xomB-3o57A:51.9","1xomA-3o57A:82.81"],["1XOM_B_CIOB601_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;MET A 347;LEU A 393;THR A 407;ILE A 410;MET A 411;PHE A 414;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.59A","1xomB-3o57A:51.9","1xomB-3o57A:82.81"],["1XOQ_A_ROFA502_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TYR A 403;THR A 407;ILE A 410;MET A 431;SER A 442;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.59A","1xoqA-3o57A:52.2","1xomB-3o57A:82.81"],["1XOQ_A_ROFA502_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ASN A 395;TRP A 406;GLN A 443","ZG2 A 506 (-4.3A);None;ZG2 A 506 (-3.3A)","0.11A","1xoqA-3o57A:52.2","1xoqA-3o57A:82.81"],["1XOQ_B_ROFB501_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;ASP A 392;LEU A 393;PRO A 396;TYR A 403;TRP A 406;THR A 407;ILE A 410;MET A 431;SER A 442;PHE A 446","None;None; ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.58A","1xoqB-3o57A:51.8","1xoqA-3o57A:82.81"],["1XOQ_B_ROFB501_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"MET A 347;ASN A 395;GLN A 443","ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-3.3A)","0.29A","1xoqB-3o57A:51.8","1xoqB-3o57A:82.81"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",10,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;MET A 411;PHE A 414;GLN A 443;PHE A 446;ILE A 450","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.52A","1xosA-3o57A:53.2","1xoqB-3o57A:82.81"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",10,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;MET A 411;PHE A 414;MET A 431;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.57A","1xosA-3o57A:53.2","1xosA-3o57A:93.83"],["1XOS_A_VIAA1_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",9,"TYR A 233;HIS A 234;MET A 347;ASP A 392;MET A 411;PHE A 414;SER A 429;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 (-4.4A);ARS A   3 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.91A","1xosA-3o57A:53.2","1xosA-3o57A:93.83"],["1XOT_A_VDNA101_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;LEU A 393;ILE A 410;MET A 411;SER A 429;MET A 431;SER A 442;GLN A 443;PHE A 446;ILE A 450","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.4A);None;ARS A   3 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.66A","1xotA-3o57A:53.5","1xosA-3o57A:93.83"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",10,"TYR A 233;HIS A 234;ASN A 395;ILE A 410;MET A 411;SER A 429;MET A 431;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ARS A   3 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.75A","1xotB-3o57A:53.4","1xotA-3o57A:93.83"],["1XOT_B_VDNB102_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",11,"TYR A 233;HIS A 234;MET A 347;LEU A 393;ASN A 395;ILE A 410;MET A 411;SER A 429;SER A 442;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.9A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ARS A   3 (-4.4A);None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.56A","1xotB-3o57A:53.4","1xotB-3o57A:93.83"],["2H42_A_VIAA901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;HIS A 234;PHE A 414;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.59A","2h42A-3o57A:36.0","1xotB-3o57A:93.83"],["2H42_C_VIAC903_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;LEU A 393;PHE A 414;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.60A","2h42C-3o57A:35.7","2h42A-3o57A:27.53"],["2WEY_A_EV1A1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",8,"TYR A 233;HIS A 234;LEU A 393;ILE A 410;GLU A 413;PHE A 414;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-4.4A);None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.87A","2weyA-3o57A:38.0","2h42C-3o57A:27.53"],["2WEY_B_EV1B1771_1","CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ILE A 410;PHE A 414;GLN A 443;PHE A 446","ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.47A","2weyB-3o57A:37.8","2weyA-3o57A:27.20"],["3B2R_A_VDNA1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"TYR A 233;HIS A 234;LEU A 393;PHE A 414;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.62A","3b2rA-3o57A:31.3","2weyB-3o57A:27.20"],["3B2R_B_VDNB1_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;HIS A 234;LEU A 393;GLN A 443;PHE A 446","None;None;None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.61A","3b2rB-3o57A:31.3","3b2rA-3o57A:28.57"],["3CZV_A_AZMA263_1","CARBONIC ANHYDRASE 13;CARBONIC ANHYDRASE 13","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"HIS A 238;HIS A 274;PHE A 446;THR A 345;VAL A 451"," ZN A   1 (-3.3A); ZN A   1 (-3.3A);ZG2 A 506 (-3.6A); MG A 504 ( 4.9A);None","1.21A","3czvA-3o57A:undetectable;3czvB-3o57A:undetectable","3b2rB-3o57A:28.57"],["3G4L_A_ROFA901_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASN A 395;PRO A 396;TYR A 403;TRP A 406;THR A 407;ILE A 410;MET A 431;SER A 442;PHE A 446","None;None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);None;ZG2 A 506 (-3.6A)","0.53A","3g4lA-3o57A:51.6","3czvA-3o57A:21.27;3czvB-3o57A:21.27"],["3G4L_A_ROFA901_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ASP A 392;LEU A 393;GLN A 443"," ZN A   1 (-2.6A);None;ZG2 A 506 (-3.3A)","0.27A","3g4lA-3o57A:51.6","3g4lA-3o57A:80.37"],["3G4L_B_ROFB902_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TRP A 406;THR A 407;ILE A 410;MET A 411;MET A 431;PHE A 446","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;ZG2 A 506 (-3.4A);ZG2 A 506 (-3.6A)","0.50A","3g4lB-3o57A:51.5","3g4lA-3o57A:80.37"],["3G4L_C_ROFC903_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;ASN A 395;PRO A 396;TYR A 403;TRP A 406;THR A 407;ILE A 410;MET A 431","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 (-4.3A);ZG2 A 506 ( 4.5A);None;None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A)","0.33A","3g4lC-3o57A:51.7","3g4lB-3o57A:80.37"],["3G4L_C_ROFC903_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"SER A 442;GLN A 443;PHE A 446","None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.43A","3g4lC-3o57A:51.7","3g4lC-3o57A:80.37"],["3G4L_D_ROFD904_0","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",12,"TYR A 233;HIS A 234;MET A 347;ASP A 392;LEU A 393;PRO A 396;TRP A 406;THR A 407;ILE A 410;MET A 411;SER A 442;GLN A 443","None;None;ZG2 A 506 (-3.9A); ZN A   1 (-2.6A);None;ZG2 A 506 ( 4.5A);None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);None;None;ZG2 A 506 (-3.3A)","0.37A","3g4lD-3o57A:52.2","3g4lC-3o57A:80.37"],["3G4L_D_ROFD904_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",3,"ASN A 395;MET A 431;PHE A 446","ZG2 A 506 (-4.3A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.6A)","0.68A","3g4lD-3o57A:52.2","3g4lD-3o57A:80.37"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ILE A 410;MET A 431;GLN A 443;PHE A 446;ILE A 450","ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.81A","3iakA-3o57A:51.2","3g4lD-3o57A:80.37"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"MET A 347;ILE A 410;MET A 431;GLN A 443;PHE A 446","ZG2 A 506 (-3.9A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.95A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",7,"TYR A 233;ASN A 395;ILE A 410;PHE A 414;GLN A 443;PHE A 446;ILE A 450","None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A);None","0.52A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3IAK_A_EV1A415_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4D","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",7,"TYR A 233;MET A 347;ASN A 395;ILE A 410;PHE A 414;GLN A 443;PHE A 446","None;ZG2 A 506 (-3.9A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.77A","3iakA-3o57A:51.2","3iakA-3o57A:82.81"],["3JWQ_C_VIAC901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"TYR A 233;HIS A 234;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.53A","3jwqC-3o57A:39.1","3iakA-3o57A:82.81"],["3JWQ_D_VIAD901_1","CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA;CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE CATALYTIC DOMAIN, CONE CGMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE SUBUNIT ALPHA CHIMERA","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"TYR A 233;HIS A 234;PHE A 414;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.58A","3jwqA-3o57A:39.1;3jwqD-3o57A:38.8","3jwqC-3o57A:28.30"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"PRO A 396;THR A 407;ILE A 410;MET A 431;GLN A 443;PHE A 446","ZG2 A 506 ( 4.5A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.74A","3tvxA-3o57A:52.8","3jwqA-3o57A:28.30;3jwqD-3o57A:28.30"],["3TVX_A_PNXA902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",8,"TYR A 233;LEU A 393;ASN A 395;PRO A 396;THR A 407;ILE A 410;GLN A 443;PHE A 446","None;None;ZG2 A 506 (-4.3A);ZG2 A 506 ( 4.5A);ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.40A","3tvxA-3o57A:52.8","3tvxA-3o57A:86.83"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",5,"ASN A 395;ILE A 410;MET A 431;GLN A 443;PHE A 446","ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.88A","3tvxB-3o57A:52.8","3tvxA-3o57A:86.83"],["3TVX_B_PNXB902_1","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4A","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",6,"TYR A 233;ASN A 395;ILE A 410;PHE A 414;GLN A 443;PHE A 446","None;ZG2 A 506 (-4.3A);ZG2 A 506 (-4.4A);ZG2 A 506 (-4.4A);ZG2 A 506 (-3.3A);ZG2 A 506 (-3.6A)","0.51A","3tvxB-3o57A:52.8","3tvxB-3o57A:86.83"],["4IAQ_A_2GMA2001_2","CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 1B AND E. COLI SOLUBLE CYTOCHROME B562","3o57","CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE 4B","Homo sapiens",4,"ILE A 410;THR A 407;VAL A 281;ASP A 230","ZG2 A 506 (-4.4A);ZG2 A 506 (-4.3A);None;None","1.09A","4iaqA-3o57A:undetectable","3tvxB-3o57A:86.83"]]